Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor

This publication has 16 references indexed in Scilit:

• Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development
  Journal of Peptide Science, 2011
• Modulation of neuropeptide Y receptors for the treatment of obesity
  Expert Opinion on Therapeutic Patents, 2009
• Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis
  Bioorganic & Medicinal Chemistry Letters, 2009
• Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists
  Bioorganic & Medicinal Chemistry Letters, 2009
• A Pair-Feeding Study Reveals That a Y5 Antagonist Causes Weight Loss in Diet-Induced Obese Mice by Modulating Food Intake and Energy Expenditure
  Molecular Pharmacology, 2007
• Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults
  Cell Metabolism, 2006
• A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice
  Proceedings of the National Academy of Sciences, 2006
• In Vitro and in Vivo Characterization of 3-{2-[6-(2-tert-Butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl}benzonitrile Hydrochloride Salt, a Potent and Selective NPY5 Receptor Antagonist
  Journal of Medicinal Chemistry, 2003
• The role of NPY in metabolic homeostasis: implications for obesity therapy
  Expert Opinion on Investigational Drugs, 2000
• Synthesis of a Spiro[cyclohex-1,1‘-isobenzofuranyl] Dopamine Receptor Antagonist
  Organic Process Research & Development, 1999